Pagani S, Cruciani L, Chianelli M, Procaccini E, Pozzilli P
Cattedra di Endocrinologia I, University of Rome La Sapienza.
Diabetes Res. 1989 Dec;12(4):199-201.
We have previously reported that 40% of diabetic patients have an impaired specific immune response after vaccination against B-hepatitis. Thymopentin (TP5), the active site of thymopoietin hormone, has been shown to increase antibody response (HbsAb) following B-hepatitis vaccination in several disease conditions. In the present study TP5 (50 mg) was administered subcutaneously three times per week to 17 diabetic patients for a week prior B-hepatitis vaccination and for three weeks afterwards. Sero-conversion was observed after the third dose of vaccine in 15 out of 17 (88%) patients and in 94% of a group of normal subjects acting as control. Although the median HbsAb titre was significantly lower in diabetics compared to normal subjects, we conclude that administration of TP5 in diabetic patients increases the rate of sero-conversion following B-hepatitis vaccination.
我们之前曾报道，40%的糖尿病患者在接种乙型肝炎疫苗后特异性免疫反应受损。胸腺五肽（TP5）是胸腺生成素激素的活性部位，已证实在多种疾病状态下，它能增强接种乙型肝炎疫苗后的抗体反应（抗-HBs）。在本研究中，17名糖尿病患者在接种乙型肝炎疫苗前一周及之后三周，每周皮下注射三次TP5（50毫克）。17名患者中有15名（88%）在接种第三剂疫苗后出现血清转化，作为对照的一组正常受试者中这一比例为94%。虽然糖尿病患者的抗-HBs滴度中位数显著低于正常受试者，但我们得出结论，糖尿病患者接种TP5可提高接种乙型肝炎疫苗后的血清转化率。
